ANRO

Alto Neuroscience, Inc. ANRO

NYSESmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Below size threshold

Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $0.0M in revenue and is scored on the micro-cap board instead.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Net income

$-27.64M

Quarter to Jun 30

Free cash flow

$-19.76M

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026
$777.59M total
Alpha Wave Global, LP
$97.85M0.0%
Commodore Capital LP
$71.87M0.0%
BlackRock, Inc.
$55.97M+218.4%
PERCEPTIVE ADVISORS LLC
$42.49M-19.9%
ADAGE CAPITAL PARTNERS GP, L.L.C.
$42.22M+315.6%
VANGUARD CAPITAL MANAGEMENT LLC
$36.67M+15.1%
Spruce Street Capital LP
$35.71M+2.1%
Vivo Capital, LLC
$31.90M+16.7%
FRANKLIN RESOURCES INC
$26.74M-8.0%
ARMISTICE CAPITAL, LLC
$22.80M-5.3%
Affinity Asset Advisors, LLC
$22.43M+70.0%
Vestal Point Capital, LP
$20.72M-62.0%
STATE STREET CORP
$18.10M+243.8%
GEODE CAPITAL MANAGEMENT, LLC
$17.90M+131.5%
72 Investment Holdings, LLC
$17.62M0.0%
NORTHERN TRUST CORP
$16.70M+33.6%
MILLENNIUM MANAGEMENT LLC
$14.73M-32.1%
Point72 Asset Management, L.P.
$13.27M0.0%
VR Adviser, LLC
$13.20M0.0%
Integral Health Asset Management, LLC
$13.20M0.0%
DRIEHAUS CAPITAL MANAGEMENT LLC
$12.87M+0.2%
Parkman Healthcare Partners LLC
$11.32MNew
Ikarian Capital, LLC
$10.75M-20.9%
PRICE T ROWE ASSOCIATES INC /MD/
$9.46M-3.5%
ORBIMED ADVISORS LLC
$6.80M+53.9%
See all 114 institutional holders →
Reading the latest SEC filing…

Key Metrics

Net Income

Q2 2026
EDGAR

EPS (Diluted)

Q2 2026
EDGAR

ROIC

Q2 2026
EDGAR

Free Cash Flow

Q2 2026
EDGAR

Debt/Equity

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/ANRO

Earnings Per Share

13fpro.ai/company/ANRO

Loading ratio trend…

ANRO insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About Alto Neuroscience, Inc. (ANRO): stock profile, AI score and financials

Alto Neuroscience, Inc. (ANRO) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. ANRO is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.0m in revenue and is scored on the micro-cap board instead. Based on the latest XBRL financial filings (Q2 2026), Alto Neuroscience, Inc. reports net income of $-27.6M, free cash flow of $-19.8M. Top institutional holders of ANRO by reported 13-F value include Alpha Wave Global, Commodore Capital, BlackRock, based on the most recent SEC filings. ANRO trades on the NYSE exchange and files with the SEC under CIK 1999480. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ANRO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Alto Neuroscience, Inc. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1999480 →